SOON-JA KAOHIMAUNU: Open Payments
NPI 1659937878 · KAMUELA, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,120 in 46 payments from 12 companies in 2025. Trend: 2023 $880 · 2024 $177 · 2025 $1,120
Food & beverage: $1,120
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $281 |
| Alkermes, Inc. | 12 | $202 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $146 |
| Lundbeck LLC | 5 | $119 |
| Neurocrine BioSciences, Inc. | 5 | $110 |
| ABBVIE INC. | 2 | $58 |
| E.R. Squibb & Sons, L.L.C. | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $33 |
Products named: ABILIFY MAINTENA, ARISTADA, REXULTI, CAPLYTA, INGREZZA, VRAYLAR, COBENFY, UZEDY.
Industry payments across HI — which companies pay providers there.
